A recent study reveals that patients who stop using popular slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle regimens.
Research printed in a leading medical journal shows that while obese people often shed a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using such treatments must be cognizant of the potential of rapid rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.
This pace of recovery implies a return to original mass in about one and a half years.
Comparing Treatments
The research, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
Scientists point out that people who shed pounds through dieting generally have a slower creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Regain
Doctors believe the mechanism of the jabs explains the heightened rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in appetite is uncontrolled, making overeating much more probable."
An Ongoing Issue?
Health authorities advise the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of relapse, the therapy is often life-long.
This opinion is reinforced by drug manufacturers, who note that the results "underscore the chronic character of obesity," similar to managing diseases like diabetes.
User Experiences
Individuals who have come off the jabs describe a sudden return of appetite.
"It was like a switch that goes on and you're instantly ravenous," recalled a patient.
This difficulty is worsened if patients have not adopted lasting lifestyle or habit changes during therapy.
Significant Interest
Survey data suggest that a significant number of people in the UK have tried these injections in the past year, with interest being substantial.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, clinicians caution that while these medications are potent tools for shedding pounds, they are not a permanent solution and lasting health benefits hinges on ongoing behavioural changes.